US Bancorp
LYEL icon

US Bancorp’s Lyell Immunopharma LYEL Stock Holding History

US Bancorp’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$815 Hold
58
– – ﹤0.01% 4004
2026
Q1 		$1.16K Hold
58
– – ﹤0.01% 3910
2025
Q4 		$1.78K Hold
58
– – ﹤0.01% 3778
2025
Q3 		$942 Hold
58
– – ﹤0.01% 3834
2025
Q2 		$513 Hold
58
– – ﹤0.01% 4002
2025
Q1 		$627 Hold
58
– – ﹤0.01% 4026
2024
Q4 		$746 Hold
58
– – ﹤0.01% 3987
2024
Q3 		$1.61K Hold
58
– – ﹤0.01% 3833
2024
Q2 		$1.69K Hold
58
– – ﹤0.01% 3743
2024
Q1 		$2.6K Buy
+58
New +$2.48K ﹤0.01% 3670
2023
Q4 		– Sell
-118
Closed -$3.47K – 4078
2023
Q3 		$3.47K Hold
118
– – ﹤0.01% 3535
2023
Q2 		$7.51K Buy
118
+76
+181% +$4.21K ﹤0.01% 3363
2023
Q1 		$1.96K Buy
42
+5
+14% +$267 ﹤0.01% 3760
2022
Q4 		$2.6K Buy
+37
New +$3.67K ﹤0.01% 3711

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

US Bancorp's LYEL Position: Q2 2026 in Review

US Bancorp held its Lyell Immunopharma (LYEL) position steady in Q2 2026 at 58 shares worth $815. The position accounts for ﹤0.01% of the portfolio, ranked #4004.

US Bancorp first reported a position in LYEL in Q4 2022 and has held it in 14 quarters since. The position peaked at $7.51K in Q2 2023. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • US Bancorp held 58 shares of Lyell Immunopharma worth $815 as of Q2 2026.
  • US Bancorp left its Lyell Immunopharma share count unchanged in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #4004 holding.
  • US Bancorp first reported a position in Lyell Immunopharma in Q4 2022 and has held it in 14 quarters since.
  • US Bancorp's Lyell Immunopharma position peaked at $7.51K in Q2 2023.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.